Premium
S‐S‐PEG‐COOH Self‐Assembled Monolayer on Gold Surface Enabled a Combined Assay for Serological EBV Antibody Isotypes
Author(s) -
Lv Hui,
Ye Lei,
Liu Qian,
Li SongGuo,
Li Tao,
Huang NaLi,
Gao Yi,
Fan LiBin,
Du WeiDong
Publication year - 2019
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201800067
Subject(s) - biochip , antibody , virology , antigen , immunoassay , serology , virus , epstein–barr virus , immunology , microbiology and biotechnology , biology , bioinformatics
Purpose Epstein‐Barr virus (EBV) is a ubiquitous human gamma herpes virus that infects human epithelial cells and B lymphocytes. It would be potentially valuable to develop novel combined assays to benefit screening for large panels of samples of EBV infectious diseases. Experimental design A simple antigen‐probed biochip that is modified with S‐S‐PEG‐COOH and is used as a label‐free high‐throughput screening method for a combined detection of EBV capsid antigen IgM antibody, capsid antigen IgG antibody, and nuclear antigen IgG antibody. Results This protein biochip has similar feasibility, sensitivity, and specificity in comparison with Liaison chemiluminescent immunoassay (CLIA). Detection limit of the EBV antibodies by the biochip is almost identical to that by CLIA‐L (2.91 U mL –1 vs 3.00 U mL –1 for EBNA‐1 IgG, 8 U mL –1 vs10 U mL –1 for EBV‐VCA IgG, and 3.5 U mL –1 vs 10 U mL –1 for EBV‐VCA IgM). Tests of the three serological antibodies against EBV by the biochip are consistent with the CLIA‐L method in 274 clinical sera, respectively. Finally, the combined biochip is successfully utilized for diagnostic identification of EBV infection in 14 patients with infectious mononucleosis (IM) and 25 patients with systemic lupus erythematosus SLE, as well as additional 10 known real‐time PCR positive patients. Conclusions and clinical relevance This biochip format will enable concurrent detection of antibodies against EBV infection and confirm infection status of EBV. It will be a versatile tool for large‐scale epidemiological screening in view of its miniaturization and high throughput.